Hovione has appointed Colin Minchom, formerly Patheon's VP of Pharmaceutical Development Services for North America, as VP of its Particle Design Business Unit. Minchom has almost 30 years experience in drug development, especially in dosage forms and delivery, and is a member of the USP expert committee on small molecules. He is also chair of the planning committee … [Read more...] about Hovione hires Colin Minchom as VP of its particle design business unit
News
Teva’s ProAir HFA MDI with dose counter approved by FDA
The FDA has approved Teva's ProAir HFA albuterol metered dose inhaler with a dose counter for the treatment and prevention of bronchospasm in patients 4 years of age and older. According to the company, the new product will be available by the end of 2012. Teva Global Respiratory Research and Development Senior VP Tushar Shah explained: “The dose counter is … [Read more...] about Teva’s ProAir HFA MDI with dose counter approved by FDA
Hi-Tech Pharmacal acquires line of homeopathic nasal sprays
Specialty pharmaceutical manufacturer Hi-Tech Pharmacal will pay a total of $2.5 million plus up to to $1.75 million in royalties to Dynova Laboratories for a line of homeopathic nasal sprays including the Sinus Buster and Allergy Buster brands, which Hi-Tech will sell through its Health Care Products OTC division. The Sinus Buster formulation includes capsaicin, and … [Read more...] about Hi-Tech Pharmacal acquires line of homeopathic nasal sprays
FDA issues warning letter on inhalable caffeine
The FDA has issued a warning letter to Breathable Foods, the manufacturer of AeroShot inhalable caffeine for "false or misleading statements in the labeling of their product." The agency is also questioning the safety of the inhaler, including the possibility that users may inhale the formulation into their lungs, that children will use the product, and that AeroShot … [Read more...] about FDA issues warning letter on inhalable caffeine
Freeman Technology launches US subsidiary
Powder characterization specialist Freeman Technology has established a US subsidiary, Freeman Technology Inc., to handle the growing North American demand for its FT4 powder rheometer. Newly-hired National Sales Specialist Mike Delancey and Applications Specialist John Yin will work with US customers. Freeman Technology Managing Director Tim Freeman explained: … [Read more...] about Freeman Technology launches US subsidiary
Mylan to appeal invalidation of inhalation solution patents
On March 1, Judge John Koeltl of the US District Court for the Southern District of New York issued a partial summary judgment in Mylan's patent infringement suit against Sunovion Pharmaceuticals, invalidating 5 of the 7 patents regarding Brovana arformoterol tartrate inhalation solution cited in the suit filed by Mylan's subsidiary Dey against Sunovion (formerly … [Read more...] about Mylan to appeal invalidation of inhalation solution patents
Teva announces positive Phase 3 results for QNASL dry nasal aerosol
Teva Pharmaceutical has announced positive results from four Phase 3 clinical studies of QNASL beclomethasone dipropionate HFA nasal aerosol for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Previously released data demonstrated that treatment with QNASL improved nasal symptom scores over the first 30 weeks of a 52-week … [Read more...] about Teva announces positive Phase 3 results for QNASL dry nasal aerosol
Positive Phase 3 results for Meda’s Dymista nasal spray
Meda has announced positive results from three studies of its Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of seasonal allergic rhinitis. The company filed both an NDA for the product, currently known as MP29-02, and an MAA in 2011. One long-term study showed that the product is well tolerated, with fewer than 3% of patients … [Read more...] about Positive Phase 3 results for Meda’s Dymista nasal spray
FluMist Quadrivalent intranasal vaccine gets FDA approval
The FDA has approved MedImmune's FluMist Quadrivalent for the prevention of influenza, making the intranasal vaccine the first approved quadrivalent flu vaccine in the US. FluMist Quadrivalent contains two type A strains and type B strains from both B/Yamagata and B/Victoria. All other currently approved seasonal flu vaccines are trivalent. University of Kentucky … [Read more...] about FluMist Quadrivalent intranasal vaccine gets FDA approval
NEJM: 200 years of asthma treatment
To celebrate its 200th anniversary, the New England Journal of Medicine (NEJM) is publishing a series of special articles reviewing progress in medicine since 1812. As part of the series, an article in the March 1, 2012 issue titled "A Patient with Asthma Seeks Medical Advice in 1828, 1928, and 2012" presents a fictionalized series of doctor's notes on the treatment … [Read more...] about NEJM: 200 years of asthma treatment